ICMR and IIL Join Forces to Develop a Vaccine Against Zika Virus
ICMR has officially partnered with IIL to develop a vaccine focused on the serious health concerns posed by the Zika virus. The collaboration aims to accelerate the clinical development process of a promising jab, with Phase I clinical trials projected to begin shortly. This initiative is vital in the fight against the spread of the Zika virus, ensuring better protections for affected communities.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.